Trial Profile
A Multicenter, Adaptive, Randomized, Blinded Controlled Trial of the Safety and Efficacy of Investigational Therapeutics for Hospitalized Patients With Acute Respiratory Distress Syndrome Associated With COVID-19
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 16 May 2023
Price :
$35
*
At a glance
- Drugs Aviptadil (Primary) ; Remdesivir (Primary)
- Indications Adult respiratory distress syndrome; COVID 2019 infections
- Focus Therapeutic Use
- Acronyms ACTIV-3b; TESICO
- 16 Dec 2022 Status changed to completed.
- 07 Nov 2022 Planned primary completion date changed from 1 Oct 2022 to 30 Nov 2022.
- 25 May 2022 Primary endpoint has not been met. (Recovery, assessed at 90 days [ Time Frame: Thru Day 90 ]), According to a NRx Pharmaceuticals media release.